Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model.

Détails

ID Serval
serval:BIB_F2A9288D83BC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model.
Périodique
Basic and Clinical Pharmacology and Toxicology
Auteur(s)
Gschwind L., Rollason V., Daali Y., Bonnabry P., Dayer P., Desmeules J.A.
ISSN
1742-7843 (Electronic)
ISSN-L
1742-7835
Statut éditorial
Publié
Date de publication
2013
Peer-reviewed
Oui
Volume
113
Numéro
4
Pages
259-265
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish Publication Type Journal Article.
Résumé
Vitamin K antagonists (VKAs) are prescribed worldwide and remain the oral anticoagulant of choice. These drugs are characterized by a narrow therapeutic index and a large inter- and intra-individual variability. P-glycoprotein could contribute to this variability. The aim of this study was to investigate the involvement of P-gp in the transport of acenocoumarol, phenprocoumon and warfarin using an in vitro Caco-2 cell monolayer model. These results were compared with those obtained with rivaroxaban, a new oral anticoagulant known to be a P-gp substrate. The transport of these four drugs was assessed at pH conditions 6.8/7.4 in the presence or absence of the P-gp inhibitor cyclosporine A (10 μM) and the more potent and specific P-gp inhibitor valspodar (5 μM). Analytical quantification was performed by LC/MS. With an efflux ratio of 1.7 and a significant decrease in the efflux (Papp B-A), in the presence of P-gp inhibitors at a concentration of 50 μM, acenocoumarol can be considered as a weak P-gp substrate. Concerning phenprocoumon, the results suggest that this molecule is a poor P-gp substrate. The P-gp inhibitors did not affect significantly the transport of warfarin. The efflux of rivaroxaban was strongly inhibited by the two P-gp inhibitors. In conclusion, none of the three VKAs tested are strong P-gp substrates. However, acenocoumarol can be considered as a weak P-gp substrate and phenprocoumon as a poor P-gp substrate.
Mots-clé
Acenocoumarol/pharmacokinetics, Anticoagulants/pharmacokinetics, Biological Transport, Caco-2 Cells, Humans, Microscopy, Electron, Transmission, Morpholines/pharmacokinetics, P-Glycoprotein/metabolism, Thiophenes/pharmacokinetics, Vitamin K/antagonists & inhibitors, Vitamin K/pharmacokinetics, Warfarin/pharmacokinetics
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/05/2014 15:58
Dernière modification de la notice
20/10/2020 11:08
Données d'usage